The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And it is publicly pressing Medicare to pay for the widespread use of the monoclonal antibodies FDA already has [...]
For more than 15 years, much of the Alzheimer’s Disease establishment has focused its attention—and hundreds of millions of research dollars—on the theory that the disease primarily is caused by the build-up of plaque, called amyloid beta, in the brain. A six-month investigation by Charles Piller, an award-winning reporter for Science magazine, finds that key research published in 2006 may [...]
Over just the past few decades, the life expectancy of people with Down Syndrome (DS) has increased from less than 30 years to nearly 60. But for many, that remarkable advancement comes at a high price. As they live longer, up to ninety percent of people with DS will have Alzheimer’s Disease. It is, in fact, the leading cause of death [...]
In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial. In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported [...]
A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients. It is a tale that could push Congress to allow Medicare to negotiate drug prices. Reuters reports that Biogen, which sells the controversial medication it calls Aduhelm, is [...]
Last month, The Food and Drug Administration (FDA) approved a controversial new drug to treat people with Alzheimer’s disease. But even though the FDA allowed the drug to be sold, Medicare is not required to pay for it. And yesterday, the Centers for Medicare & Medicaid Services (CMS) began a process to determine whether Medicare will establish a national coverage [...]
FDA’s decision last week to approve a new “Alzheimer’s disease treatment,” and the buzz that surrounds it, is a symptom of all that is wrong with the way we care for frail older adults in the US. Rather than providing the supports that people with chronic conditions desperately need, and that evidence shows works, we prefer to chase butterflies. In [...]
In a highly controversial decision, the FDA gave accelerated approval to the first drug that could slow the progression of Alzheimer’s disease. But the approval does not say the FDA thinks the drug actually will treat the disease. Rather, FDA carefully states that the drug, with the chemical name aducanumab and the brand name Aduhelm, reduces a substance on the [...]